Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Search by expertise, name or affiliation
Impact of rituximab therapy for treatment of acute humoral rejection
Z. Kaposztas
, H. Podder
,
S. Mauiyyedi
, O. Illoh
, R. Kerman
, M. Reyes
, V. Pollard
, Barry D. Kahan
Research output
:
Contribution to journal
›
Review article
›
peer-review
123
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Impact of rituximab therapy for treatment of acute humoral rejection'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Acute Rejection
100%
Plasmapheresis
100%
Rituximab
100%
Rituximab Therapy
100%
Antibody-mediated Rejection
66%
Graft Survival
33%
Demographic Characteristics
16%
Patient Survival
16%
Kidney
16%
Multivariate Analysis
16%
Demographic Variables
16%
Retrospective Analysis
16%
No Significant Difference
16%
Serum Creatinine
16%
Clinical Variables
16%
Infectious Complications
16%
Kidney Transplant Recipients
16%
Antilymphocyte Antibodies
16%
Allograft Loss
16%
Serum IgG Level
16%
Rejection Episodes
16%
Intravenous gammaglobulin
16%
Banff Classification
16%
Pulse Steroids
16%
Rejection Treatment
16%
Immunology and Microbiology
Rituximab
100%
Plasmapheresis
85%
Antibody Mediated Rejection
57%
Intravenous Immunoglobulin
14%
Pulse Rate
14%
Normal Value
14%
Anti-Lymphocyte Globulin
14%
Creatinine Blood Level
14%
Allograft
14%
Neuroscience
Rituximab
100%
Intravenous Immunoglobulin
14%
Creatinine
14%
Anti-Lymphocyte Globulin
14%